Laddar...
Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
INTRODUCTION: LC350189 is a novel selective xanthine oxidase inhibitor under clinical development for the management of hyperuricemia in gout patients. The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of the drug in healthy subjects. METHODS: A dose-bloc...
Sparad:
| I publikationen: | Drug Des Devel Ther |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4560520/ https://ncbi.nlm.nih.gov/pubmed/26357467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S86884 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|